

**FOR IMMEDIATE RELEASE**

## **Affimed Announces Fourth Quarter and Year End 2014 Financial Results Conference Call**

*Heidelberg, Germany, March 18, 2015* – Affimed N.V. (Nasdaq: AFMD) today announced that on March 25, 2015, the Company will release its financial results for the fourth quarter and year ended December 31, 2014. The Company’s management will host a conference call to discuss the Company’s financial results and recent corporate developments on Wednesday, March 25, 2015 at 8:30 a.m. EST. The call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code 1539911.

Local - Amsterdam, the Netherlands:	+31(0)20 713 2789
Local - Copenhagen, Denmark:	+4538 48 75 13
Local – Frankfurt, Germany:	+49(0)69 2222 10620
Local - Geneva, Switzerland:	+41(0)22 567 5431
Local - London, U.K.:	+44(0)20 7136 2050
Local - New York City, U.S.A.:	+1 646 254 3360
Local - Paris, France:	+33(0)1 70 48 01 66

A webcast of the conference call can be accessed in the “Events” section on the “Media” page of the Affimed website at <http://www.affimed.com/events.php>. A replay of the webcast will be available on Affimed’s website shortly after the conclusion of the call and will be archived on the Affimed website for 30 days following the call.

### **About Affimed**

Affimed is a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed’s product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body’s own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called Natural Killer cells, or NK-cells, and T-cells. Affimed’s proprietary, next-generation bispecific antibodies, called TandAbs for their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells. Affimed has focused its research and development efforts on three proprietary TandAb programs for which it retains global commercial rights. For more information, please visit [www.affimed.com](http://www.affimed.com)

**Contact:**

Affimed N.V.

Adi Hoess, CEO

Phone: +49 6221 65307-0

E-Mail: [IR@affimed.com](mailto:IR@affimed.com)

**Media requests:**

Anca Alexandru or Gretchen Schweitzer

MacDougall Biomedical Communications

Phone: +49 89 2424 3494 or

+49 163 613 3359

E-Mail: [aalexandru@macbiocom.com](mailto:aalexandru@macbiocom.com)